[go: up one dir, main page]

TNSN04054A1 - Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline - Google Patents

Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline

Info

Publication number
TNSN04054A1
TNSN04054A1 TNP2004000054A TNSN04054A TNSN04054A1 TN SN04054 A1 TNSN04054 A1 TN SN04054A1 TN P2004000054 A TNP2004000054 A TN P2004000054A TN SN04054 A TNSN04054 A TN SN04054A TN SN04054 A1 TNSN04054 A1 TN SN04054A1
Authority
TN
Tunisia
Prior art keywords
tetrahydroisoquinol
dimethoxy
pyridyl
amino
methanesulfonamido
Prior art date
Application number
TNP2004000054A
Other languages
English (en)
Inventor
Janet Sarah Smith
Michael John Humphrey
Ross James Macrae
John Douglas Davis
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2002/004040 external-priority patent/WO2003032956A1/fr
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN04054A1 publication Critical patent/TNSN04054A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/04Dehydrogenation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENTION PROPOSE UNE FORMULATION PHARMACEUTIQUE A LIBERATION CONTROLEE POUR ADMINISTRATION ORALE; COMPRENANT DE LA 4-AMINO-6;7- DIMETHOXY-2-(5-METHANE-SULFONAMIDO-1;2;3;4-TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL)-QUINAZOLINE; OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; ET UN ADJUVANT; DILUANT OU SUPPORT PHARMACEUTIQUEMENT ACCEPTABLE; LADITE FORMULATION ETANT CARACTERISEE EN CE QU'ELLE EST ADAPTEE A LIBERER AU MOINS 50% EN POIDS DE LA 4-AMINO-6;7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1;2;3;4;-TETRAHYDROISOQUINOL-2-YL) –5-(2-PYRIDYL)-QUINAZOLINE; OU DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE; AU BOUT DE 6 HEURES DANS L'APPAREIL 1 DECRIT DANS LA PHARMACOPEE DES ETATS-UNIS D'AMERIQUE 24 (2000); PAGES 1941-1943; COMPRENANT DES RECIPIENTS D'UN LITRE; DES PANIERS A MAILLES N° 40 (OUVERTURES DE 0;4 MM); A UNE VITESSE DE ROTATION DE 100 TR/MIN; ET AVEC UN MILIEU DE DISSOLUTION CONSISTANT EN 900 ML D'ACIDE CHLORYDRIQUE 0;01 M CONTENANT 0;7% EN POIDS/VOLUME DE CHLORURE DE SODIUM A 37° C. LES FORMULATIONS CONFORMES A LA PRESENTE INVENTION CONVIENNENT AU TRAITEMENT DE L'HYPERPLASIE PROSTATIQUE BENIGNE (HPB).
TNP2004000054A 1955-01-14 2004-04-07 Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline TNSN04054A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1244/55A GB793192A (en) 1955-01-14 1955-01-14 Improvements in or relating to the oxidative treatment of organic substances
PCT/IB2002/004040 WO2003032956A1 (fr) 2001-10-11 2002-09-30 Formulations pharmaceutiques destinees a la liberation controlee de 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
TNSN04054A1 true TNSN04054A1 (fr) 2006-06-01

Family

ID=6709033

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000054A TNSN04054A1 (fr) 1955-01-14 2004-04-07 Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline

Country Status (2)

Country Link
GB (1) GB793192A (fr)
TN (1) TNSN04054A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019729A1 (fr) * 1995-11-28 1997-06-05 Ici Canada Inc. Procede et appareil d'epuration d'acide residuel

Also Published As

Publication number Publication date
GB793192A (en) 1958-04-09

Similar Documents

Publication Publication Date Title
NO174916B (no) Fremgangsmåte for fremstilling av et medikament for behandling av öyenbetennelser
FR2439189A1 (fr) Nouveaux derives de la 5h-2,3-benzodiazepine et procede pour la preparation de ces derives et compositions pharmaceutiques les contenant
NO941918L (no) Indolderivater
BE899635A (fr) Compositions pharmaceutiques.
BE900660A (fr) Composition therapeutique pour le traitement des sequelles d'intoxication.
BE1002109A3 (fr) Composition pharmaceutique a activite analgesique.
TNSN96161A1 (fr) Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant.
KR920008026A (ko) 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
WO1982001821A1 (fr) Composition pharmaceutiques antimycotiques synergiques et leur procede de preparation
BG51341A3 (bg) Метод за получаване на фармацевтичен състав
KR890003382A (ko) 항 비루스성 화합물
FR2438654A1 (fr) Compose de 2-methyl-dihydropyridine, procedes pour son obtention et composition pharmaceutique contenant ce compose
TNSN04054A1 (fr) Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6, 7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline
FR2500303A1 (fr) Le chlorure de gallium, nouveau medicament anti-cancereux
FR2685918B1 (fr) Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
MA27075A1 (fr) Formulations pharmaceutiques pour la liberation controlee de la 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) - quinazoline
Mulvaney et al. Urinary phenazopyridine stones: a complication of therapy
US3996356A (en) Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
TNSN00015A1 (fr) Nouveaux sels de morpholinobenzamide
US3737552A (en) Method of treating gonorrhea
Earle et al. Studies on the chemotherapy of the human malarias. X. The suppressive antimalarial effect of paludrine
JP3061445B2 (ja) 血管拡張剤
GB1313164A (en) Blood plasma substitute
KR860000070A (ko) 종양 발육억제 조성물
EP0830144A1 (fr) Compositions pulverulentes et solubles dans l'eau et leurs applications